 HIGH POINT, N.C., Nov. 04, 2020 GLOBE NEWSWIRE -- vTv Therapeutics Inc. Nasdaq: VTVT today reported baseline characteristics for the enrolled subjects in the ongoing Elevage clinical study of azeliragon as a potential treatment for mild Alzheimers disease AD in people with type 2 diabetes NCT03980730. The data demonstrate that the patients enrolled in Elevage n43 have similar baseline characteristics to those in the STEADFAST A-study type 2 diabetes T2D subgroup NCT02080364 n47. As the company reported in October 2018, data from this subgroup demonstrated nominally significant differences favoring azeliragon compared with placebo on the ADAS-cog11, an instrument used to evaluate cognition. The goal of the Elevage study is to confirm the results of these retrospective analyses in a 6-month Phase 2 study prior to initiating a Phase 3 study. 